{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:06:13Z","timestamp":1792638373266,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T00:00:00Z","timestamp":1436400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.seizure.2015.07.001","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T00:07:10Z","timestamp":1436573230000},"page":"72-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Wendy Waldman","family":"Zadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Escartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tennigkeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Borghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dedeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2015.07.001_bib0120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.seizure.2015.07.001_bib0125","unstructured":"UCB Pharma.Vimpat\u00ae (lacosamide tablets, injection, oral solution) [U.S. prescribing information]. Smyrna: UCB, Inc. http:\/\/www.vimpat.com\/pdf\/vimpat_PI.pdf. Last updated February 2015."},{"key":"10.1016\/j.seizure.2015.07.001_bib0130","unstructured":"UCB Pharma. Vimpat\u00ae (lacosamide) EMA Summary of Product Characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000863\/WC500050338.pdf. Last updated January 2015."},{"key":"10.1016\/j.seizure.2015.07.001_bib0135","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.001_bib0140","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.001_bib0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.001_bib0150","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","article-title":"Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials","volume":"24","author":"Chung","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2015.07.001_bib0155","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.07.001_bib0160","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/good-clinical-practice.html. Last updated June 1996."},{"key":"10.1016\/j.seizure.2015.07.001_bib0165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1525-5050(03)00004-0","article-title":"Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behavior"},{"key":"10.1016\/j.seizure.2015.07.001_bib0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yebeh.2011.12.023","article-title":"Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures","volume":"23","author":"Borghs","year":"2012","journal-title":"Epilepsy Behavior"},{"key":"10.1016\/j.seizure.2015.07.001_bib0175","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"10.1016\/j.seizure.2015.07.001_bib0180","first-page":"114","article-title":"Lacosamide added to a monotherapy in epilepsy patients with partial-onset seizures: final analysis of the VITOBA study","volume":"55","author":"Noack-Rink","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.001_bib0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide","volume":"29","author":"Villanueva","year":"2013","journal-title":"Epilepsy Behavior"},{"key":"10.1016\/j.seizure.2015.07.001_bib0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2013.11.016","article-title":"Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?","volume":"31","author":"Brodie","year":"2014","journal-title":"Epilepsy Behavior"},{"key":"10.1016\/j.seizure.2015.07.001_bib0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.07.001_bib0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40261-014-0255-5","article-title":"Early add-on lacosamide in a real-life setting: results of the REALLY study","volume":"35","author":"Villanueva","year":"2015","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl. 10","key":"10.1016\/j.seizure.2015.07.001_bib0205","first-page":"113","article-title":"Improvement in patient-reported outcomes seen in patients responding to lacosamide: pooled QOLIE-31, SSS and PGIC data from 3 phase II\/III clinical trials","volume":"50","author":"de la Loge","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2015.07.001_bib0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40261-015-0277-7","article-title":"Effect of age and sex on lacosamide pharmacokinetics in healthy adult subjects and adults with focal epilepsy","volume":"35","author":"Schaefer","year":"2015","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.seizure.2015.07.001_bib0215","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.eplepsyres.2014.06.018","article-title":"Adjunctive lacosamide--5 years\u2019 clinical experience","volume":"108","author":"Stephen","year":"2014","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.seizure.2015.07.001_bib0220","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2015.07.001_bib0225","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behavior"},{"key":"10.1016\/j.seizure.2015.07.001_bib0230","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Research"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131115001648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131115001648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:45:40Z","timestamp":1761011140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131115001648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":23,"alternative-id":["S1059131115001648"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2015.07.001","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2015.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}